TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2696231
Drug: Cefazolin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (4 X 0.5 g intravenously)
Study: 29353709
Drug: Telenursing services
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenursing services (N=48) - weekly contact via telephone to motivate self-monitoring and healthy lifestyle.
Study: 19890370
Drug: Amlodipine/benazepril (5/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril (5/20 or 10/40 mg daily)
Study: 19890370
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 or 10 mg daily)
Study: 15776333
Drug: Immediate pre-exercise,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate pre-exercise, orally ingested sodium load (164 mEq Na+) (IPOSL), equivalent to 10 ml per kilogram of body weight.
Study: 15776333
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (Pl), hypotonic (94 mOsm . kg (‐1)), no-sodium, equivalent to 10 ml . kg (‐1) body weight.
Study: 10333375
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery and radiotherapy
Study: 2016227
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methylphenidate (0.4 mg/kg)
Study: 29412045
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use for more than 1 year
Study: 18408362
Drug: Deferasirox (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (5-30 mg/kg/day)
Study: 31332099
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen (paclitaxel 90 mg/m2 on days 1, 8, and 15 with carboplatin AUC 6 on day 1 of every 4 weeks)
Study: 31332099
Drug: Biweekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly regimen (paclitaxel 135 mg/m2 with carboplatin AUC 3 on days 1 and 15 of every 4 weeks)
Study: 29634142
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with alpha-blockers
Study: 29634142
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-alpha reductase inhibitors and alpha-blockers
Study: 29634142
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination drug Duodart
Study: 28797281
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) applied to the affected leg for 45 minutes daily, 5 days a week for 3 weeks at a frequency of 10 Hz and pulse width of 200 μs.
Study: 23835365
Drug: Polaprezinc (PLZ)
Normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (PLZ) 150 mg/d (116 mg CAR and 34 mg zinc)
Study: 23835365
Drug: L-carnosine (CAR)
Normalized name: L-Carnosine
DrugBank: Carnosine (DB11695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnosine (CAR) 116 mg/d
Study: 17023720
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation (250 mg vitamin C, 100 IU vitamin E, 37.5 mg selenium)
Study: 17023720
Drug: Garlic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplementation (200 mg aged garlic extract and 1 mg steam-distilled garlic oil, twice daily)
Study: 17023720
Drug: Short-term amoxicillin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term amoxicillin (1 g) and omeprazole (20 mg) treatment
Study: 10745279
Drug: Yoghurt fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt fermented with one strain of Enterococcus faecium and two strains of Streptococcus thermophilus (CAUSIDO(R) culture), GAIO(R) (G)
Study: 26304905
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills (PP)
Study: 26551263
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of velpatasvir plus ribavirin
Study: 26551263
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of velpatasvir once daily
Study: 26551263
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of velpatasvir plus ribavirin
Study: 21134456
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine formulations (PRP-T, 12μg; PRP-OMPC, 3μg or 6μg)
Study: 21134456
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine formulations (PRP-OMPC, 3μg or 6μg)
Study: 21134456
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.5mL intramuscular dose of diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b+hepatitis B vaccine)
Study: 17174559
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion at a dose of 0.1mg/kg/h during rewarming period of CPB
Study: 9813513
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SNP infusion)
Study: 27646937
Drug: Remifentanil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.1 μg/kg/min
Study: 27646937
Drug: Remifentanil 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.2 μg/kg/min
Study: 27646937
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 μg/kg/min
Study: 27646937
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including all doses of remifentanil)
Study: 27941730
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg/day) for 12 weeks
Study: 17499360
Drug: Succimer chelation
Normalized name: Succimer
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Succimer chelation therapy
Study: 15479125
Drug: Lp(a) levels
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) levels in women with aCAD(+), median 442 units/l, p<0.001
Study: 15479125
Drug: Lp(a) levels
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) levels in men with aCAD(+), median 274 units/l, p<0.001
Study: 15479125
Drug: HDL cholesterol
Normalized name: HDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL cholesterol levels in women with aCAD(+), 1.09 mmol/l, p<0.05
Study: 15479125
Drug: Triglycerides in
Normalized name: omega-3-triglycerides incl. other esters and acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides in women with aCAD(+), 1.82 mmol/l, p<0.05
Study: 15479125
Drug: Lp(a) levels
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) levels in men with aCAD(-), median 138 units/l
Study: 15479125
Drug: Lp(a) levels
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) levels in women with aCAD(-), median 145 units/l
Study: 11463010
Drug: Continued oral
Normalized name: Entex HC Discontinued Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued oral anticoagulant therapy for 9 additional months
Study: 11463010
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of oral anticoagulant therapy after 3 months
Study: 9750033
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (cisplatin + etoposide) plus radiotherapy followed by additional radiotherapy and 2 additional cycles of chemotherapy
Study: 8032575
Drug: Euphylong (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphylong (once-daily evening administration)
Study: 28300856
Drug: Halobetasol Propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol Propionate Lotion, 0.05% (HBP Lotion)
Study: 28300856
Drug: Halobetasol Propionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol Propionate Cream, 0.05% (HBP Cream)
Study: 12492745
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg
Study: 11899817
Drug: Intensive peloidobalneotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive peloidobalneotherapy (daily procedures with 4-5 hours interval)
Study: 10421182
Drug: Calf-thigh sequential
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf-thigh sequential pneumatic compression
Study: 2285255
Drug: IL-2 plus
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 plus MLT (10 mg/day orally at 8.00 p.m.)
Study: 31122901
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus chemotherapy (carboplatin and nab-paclitaxel)
Study: 25148955
Drug: FVOO (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVOO (30 mL, OOPC=961 mg/kg)
Study: 25148955
Drug: VOO (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: VOO (30 mL, OOPC=289 mg/kg)
Study: 25148955
Drug: FVOO (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVOO (30 mL)
Study: 23511366
Drug: Left lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left lateral position with 2 mL hyperbaric bupivacaine 0.5%
Study: 23511366
Drug: Modified lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified lateral position with 2 mL hyperbaric bupivacaine 0.5%
Study: 23511366
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position with 2 mL hyperbaric bupivacaine 0.5%
Study: 19894328
Drug: Menatretenone 45
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatretenone 45 mg twice a day
Study: 16735933
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of hormone therapy (group 1)
Study: 16735933
Drug: Gradual discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual discontinuation of hormone therapy (group 2)
Study: 31064779
Drug: glasdegib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: glasdegib + low-dose cytarabine (LDAC)
Study: 23512892
Drug: Leptin administration
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin administration via subcutaneous injection twice daily for 16 weeks
Study: 21811161
Drug: Standard-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose regimen (rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, all twice daily for 10 days)
Study: 21811161
Drug: Half-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose regimen (rabeprazole 10 mg, amoxicillin 500 mg, clarithromycin 250 mg, all twice daily for 10 days)
Study: 21811161
Drug: Standard-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose regimen
Study: 21811161
Drug: Half-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose regimen
Study: 10199760
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg)
Study: 2856542
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose beclomethasone (200 micrograms bid)
Study: 2856542
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose beclomethasone (1000 micrograms bid)
Study: 30921005
Drug: Lycopene supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplements (15 mg capsules/day)
Study: 30921005
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea supplements (600 mg/day epigallocatechin gallate)
Study: 28851296
Drug: Procalcitonin antibiotic
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin antibiotic prescribing guideline
Study: 28449281
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg varenicline
Study: 17022368
Drug: Streblus asper
Normalized name: Asper-Flex
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Streblus asper leaf extract (SAE) solution (80 mg/ml)
Study: 8987188
Drug: Avocado enriched
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocado enriched diet (2000 Kcal, lipids 53% MFA 49 g saturated/unsaturated ratio 0.54)
Study: 8987188
Drug: Isocaloric control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric control diet (MFA 34 g, saturated/unsaturated ratio 0.7)
Study: 23306427
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 100 mg of rebamipide three times a day
Study: 23306427
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 100 mg celecoxib twice daily
Study: 21292168
Drug: Alvimopan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 0.5 mg twice daily
Study: 21292168
Drug: Alvimopan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 0.5 mg once daily
Study: 19719843
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol with rFSH and pre‐treatment with hCG (200 IU/day for 7 days)
Study: 19719843
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol with rFSH and pre‐treatment with hCG
Study: 15226339
Drug: Heparin every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin every 2 weeks for 12 months
Study: 11520428
Drug: Garlic supplement
Normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplement
Study: 23737323
Drug: Topical nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nifedipine ointment (5 min twice daily for 4 weeks)
Study: 23737323
Drug: Topical nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nifedipine ointment
Study: 23737323
Drug: Lateral internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral internal sphincterotomy (LIS) and Topical nifedipine ointment
Study: 22078193
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 days followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses
Study: 9442429
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of metronidazole 25% dental gel
Study: 1545086
Drug: Clean Room
Normalized name: Pharma-Wipe Clean Room 12 x 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean Room (CR) therapy
Study: 22723578
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin (INS group)
Study: 22723578
Drug: Triple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple oral therapy (TOT group)
Study: 21171670
Drug: Lesogaberan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan (150 mg twice daily)
Study: 21171670
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lesogaberan and esomeprazole
Study: 1695070
Drug: Terfenadine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (300 mg twice daily)
Study: 1695070
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg or 300 mg)
Study: 686240
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of tinidazole twice daily for 7 days
Study: 18471084
Drug: Magnitude, frequency,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnitude, frequency, or subclass of PfMSP5 or PvMSP5 IgG antibodies
Study: 11171280
Drug: Methionine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine (0.1 mg/kg)
Study: 31465720
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g)
Study: 23937319
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + EV (6 mg/day on day 10-14)
Study: 23937319
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + placebo (vitamin B)
Study: 23937319
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + EV
Study: 15151838
Drug: V+D+M treatment
Normalized name: M-End Max D
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V+D+M treatment protocol
Study: 1971165
Drug: Terfenadine (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (180 mg)
Study: 2571320
Drug: Terfenadine (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (180 mg) plus Flurbiprofen (100 mg)
Study: 9021434
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg)
Study: 15288334
Drug: Delayed preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed preparation
Study: 31032601
Drug: Successful percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful percutaneous treatment of CTO
Study: 27914274
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin E2 gel (Prepidil®, dinoprostone) before labor (PGE group, n=90)
Study: 27914274
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (unmedicated group, n=90)
Study: 11186596
Drug: Combined walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined walking and conversation treatment
Study: 6307178
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg daily for 3 consecutive days every 2 weeks)
Study: 23499231
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) with body image component using Virtual Reality techniques
Study: 23499231
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) without body image component
Study: 16374671
Drug: Participants told
Normalized name: toldimfos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants told they may or may not be receiving a drug (conditional expectations)
Study: 7908244
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg (5-10 years) or 20 mg (11-15 years) once daily before breakfast
Study: 3530644
Drug: Five bronchodilator
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five bronchodilator drugs (specific drugs not mentioned)
Study: 3530644
Drug: Metered-dose inhalers
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhalers delivery method
Study: 27489153
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with a booklet detailing locally available social activities.
Study: 30789856
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg
Study: 25041486
Drug: Ilaprazole 20
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 20 mg
Study: 25041486
Drug: Ilaprazole 40
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 40 mg
Study: 18448989
Drug: Humerus segment
Normalized name: Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humerus segment with platelet gel
Study: 8973987
Drug: 0.6 gm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 gm, 1.2 gm, and 1.8 gm doses of oxaprozin given on an empty stomach in a randomized, crossover trial (n = 35)
Study: 8973987
Drug: 1.2 gm
Normalized name: Omtryg 1.2 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 gm once daily for 8 days (n = 12)
Study: 8973987
Drug: 1.8 gm
Normalized name: Calcionate 1.8 GM per 5 ML Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 gm once daily for 8 days (n = 24)
Study: 9818712
Drug: Multiple-dose administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose administration
Study: 9818712
Drug: Single-dose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration
Study: 8973987
Drug: Repetitive dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive dosing of oxaprozin
Study: 30222367
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg/d)
Study: 18834786
Drug: Oral coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral coenzyme Q10, 150 to 180 mg/d, for 7 to 10 days preoperatively